HomeMarkets Markets In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients By news November 12, 2023 0 307 FacebookTwitterPinterestWhatsApp Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected149,761FansLike396,312FollowersFollow2,560SubscribersSubscribe Latest Articles Hot Items Has the Fed fixed the economy yet? And other burning economic questions for 2026 Market News Trump’s Tangled Web of Deal-Making, Policy and Riches Energy World’s Largest Nuclear Plant Coming Back Online in Japan Energy The Beginning of the End of the Shadow Fleet AI 2026 Predictions Markets Facts vs. Clicks: How Algorithms Reward Extremism (updated, shared) Markets Wrap It Up Wednesday – Putting 2025 To Bed Markets Tuesday: 2025 – The Year in Review AI AI agents arrived in 2025 – here’s what happened and the challenges ahead in 2026 Climate West Coast levee failures show growing risks from America’s aging flood defenses Markets ‘I Was Just So Naïve’: Inside Marjorie Taylor Greene’s Break With Trump Market News Help Wanted – The US Needs More Workers Energy The Beginning of Venezuela’s End Markets Monday Market Movement – Ending 2025 With A Bang! Load more